CATALOGO DEI PRODOTTI DELLA RICERCA

BONIFACIO, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.162
EU - Europa 8.952
AS - Asia 7.449
SA - Sud America 1.110
AF - Africa 203
OC - Oceania 55
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 27.940
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.941
RU - Federazione Russa 3.560
SG - Singapore 2.745
CN - Cina 2.260
GB - Regno Unito 1.576
IT - Italia 1.042
BR - Brasile 877
HK - Hong Kong 714
VN - Vietnam 664
DE - Germania 547
SE - Svezia 492
FR - Francia 470
IE - Irlanda 416
FI - Finlandia 308
KR - Corea 242
BD - Bangladesh 168
IN - India 158
CA - Canada 119
UA - Ucraina 119
NL - Olanda 96
AR - Argentina 88
ID - Indonesia 74
PL - Polonia 69
JP - Giappone 65
MX - Messico 64
TR - Turchia 59
AU - Australia 49
ES - Italia 45
BE - Belgio 42
IQ - Iraq 42
NG - Nigeria 40
AT - Austria 36
ZA - Sudafrica 33
EC - Ecuador 32
CO - Colombia 31
PK - Pakistan 28
VE - Venezuela 27
UZ - Uzbekistan 25
CL - Cile 24
IR - Iran 24
MA - Marocco 23
TG - Togo 22
PH - Filippine 19
TN - Tunisia 18
MY - Malesia 16
RO - Romania 16
AZ - Azerbaigian 15
GR - Grecia 15
JO - Giordania 14
NP - Nepal 14
SA - Arabia Saudita 14
CZ - Repubblica Ceca 13
DZ - Algeria 13
BJ - Benin 12
AE - Emirati Arabi Uniti 11
LT - Lituania 11
PE - Perù 11
CH - Svizzera 10
DK - Danimarca 10
KZ - Kazakistan 10
PY - Paraguay 9
EG - Egitto 8
IL - Israele 8
JM - Giamaica 8
BO - Bolivia 7
CG - Congo 7
KE - Kenya 7
NO - Norvegia 7
RS - Serbia 7
SI - Slovenia 7
AL - Albania 6
CR - Costa Rica 6
KG - Kirghizistan 6
LV - Lettonia 6
OM - Oman 6
TH - Thailandia 6
BH - Bahrain 5
ET - Etiopia 5
NZ - Nuova Zelanda 5
PT - Portogallo 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
EU - Europa 4
HU - Ungheria 4
LK - Sri Lanka 4
PA - Panama 4
QA - Qatar 4
UY - Uruguay 4
AM - Armenia 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
HR - Croazia 3
KH - Cambogia 3
LA - Repubblica Popolare Democratica del Laos 3
LY - Libia 3
NI - Nicaragua 3
SN - Senegal 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
Totale 27.898
Salva come PNG Salva come JPEG
Città #
Singapore 1.388
Southend 1.303
Ashburn 1.244
Moscow 1.160
San Jose 1.022
Chandler 968
Dallas 953
Hong Kong 704
Beijing 514
Woodbridge 505
Dublin 414
Verona 409
The Dalles 403
Ann Arbor 329
Council Bluffs 320
Jacksonville 268
Houston 267
New York 224
Wilmington 195
Ho Chi Minh City 194
Los Angeles 183
Lawrence 172
Princeton 172
Hanoi 141
Jinan 133
Nanjing 123
Shenyang 123
Buffalo 101
Munich 97
Helsinki 89
Redmond 88
São Paulo 84
Redondo Beach 78
Sindelfingen 78
Columbus 77
Santa Clara 77
Hebei 76
Tianjin 69
Milan 63
Tokyo 59
Warsaw 58
Orem 54
Zhengzhou 54
Changsha 49
London 47
Bologna 46
Falls Church 46
Nanchang 46
Jakarta 45
Montreal 45
Taizhou 45
Chicago 44
Fuzhou 44
Ningbo 44
Guangzhou 43
Redwood City 43
Brussels 41
Hangzhou 41
Dong Ket 40
Nuremberg 39
Chennai 38
Frankfurt am Main 38
Rome 38
Haikou 37
Turku 37
Seoul 36
Seattle 35
San Francisco 34
Atlanta 32
Norwalk 31
Rio de Janeiro 31
Abuja 30
Denver 30
Amsterdam 27
Belo Horizonte 27
Jiaxing 27
Kent 27
Mexico City 27
Perth 26
Boardman 25
Taiyuan 25
Johannesburg 24
Stockholm 24
Tashkent 24
Phoenix 23
Poplar 23
Toronto 23
Boston 22
Falkenstein 22
Lomé 22
Groningen 21
Da Nang 18
Shanghai 17
Vienna 17
Dearborn 16
Kyiv 16
Provo 16
Biên Hòa 15
Brasília 15
Düsseldorf 15
Totale 16.812
Salva come PNG Salva come JPEG
Nome #
Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. 333
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 254
Role of GSK-3 signalling in non-promyelocitic acute myeloid leukemia (AML) cell response to chemotherapy 252
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 250
A study of the crosstalk between CD30 and CXCR4 248
Notch singalling inhibition as a multi-target therapy to overcome bone marrow microenvironment-mediated drug resistance in AML 247
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia 246
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 246
Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy 243
A preliminary experience with the HyperCHiDAM Verona intensive chemotherapy regimen in heavily pretreated refractory Hodgkin's lymphoma 237
Inhibition of GSK-3 Signalling Enhances Sensitivity of Non-Promyelocitic Acute Myeloid Leukemia (AML) Cell to Chemotherapy 234
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 230
Clonal mast cell disorders limited to bone marrow: not a negligible disease. 226
Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma. 225
Rational of targeting WNT/beta-catenin signaling in acute myeloid leukemia (AML) 219
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 217
ALK-positive anaplastic large cell lymphoma with PAX-5 expression: report of a case 216
Inhibition of Notch signalling overcomes bone marrow stromal-mediated anti-apoptotic and chemoresistance effects in AML. 213
CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin 213
Autoimmune complications are frequent in splenic and nodal marginal zone lymphomas 211
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia and may provide prognostic informations 211
A simple score predicts clonal mast cell disorders in patients with systemic reactions to Hymenoptera venom without skin lesions 210
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 207
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 204
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 202
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 200
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 200
Value of flow cytometry in the diagnosis of indolent systemic mastocytosis. 199
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 196
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis. 191
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 191
Inhibition of Notch signaling enhances chemosensitivity in B cell precursor acute lymphoblastic leukemia 188
α-bisabolol is an effective proapoptotic agent against BCR-ABL+ cells in synergism with Imatinib and Nilotinib 187
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 186
The Sesquiterpene Oil {alpha}-Bisabolol Induces Apoptosis of B-Chronic Lymphocytic Leukemia Primary Cells 185
Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway 185
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 185
A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years’ Experience of the GISM Network 185
Back to life – Living, treating, managing myelofibrosis: the burden of illness for patients and their families 184
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) 182
The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis 182
Improved detection of the C-KIT D816V mutation using allele-specific arms real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. 181
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 181
Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. 179
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements 179
Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia 179
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 177
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 177
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 176
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 176
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 174
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 174
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 173
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis 172
TP53 mutations in adult acute lymphoblastic leukemia (ALL) are relatively frequent in molecularly negative case of both B- and T-lineage and correlate with poor response to induction therapy 171
Bone Disease in Mastocytosis 170
Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells 167
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 167
Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis 166
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis 166
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 166
Short-term, intensive chemotherapy regimen is equally effective in Burkitt lymphoma (BL) and in the novel WHO 2008 entity “B-cell lymphoma intermediate between DLBCL and BL". 165
Molecular “warning” CML patients: a retrospective study of Gruppo Triveneto LMC. 165
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 165
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 164
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 162
Mitochondrial-Mediated Apoptosis by the Sesquiterpene Oil {alpha}-Bisabolol and Its Synergism with Imatinib and Nilotinib In BCR-ABL+ Cells. 160
Unexpected subacute leucoencephalopathy following intrathecal methotrexate and cytarabine administration in a patient homozygous for MTHFR 677C→T polymorphism. 160
A critical comparison of Sokal, Euro, and Eutos risk scores in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. 159
Systemic mastocytosis: a muldisciplinary approach (Review) [Lamastocitosi sistemica: Un approccio multidiscliplinare] 158
Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis 158
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 157
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 157
Serum tryptase levels differently change over time in indolent systemic mastocytosis with or without skin lesions. 156
Regulative loop between beta-catenin and protein tyrosine phosphatase receptor type gamma (PTPRG) in chronic myeloid leukemia 156
The impact of a 7-day prednisone (PDN) pretreatment in adult (less than 60y) acute lymphoblastic leukemia (ALL) therapy: results of LAL2000 vs LAL0496. 155
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 155
Modified HyperCVAD and rituximab for the treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. 154
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 153
EUTOS Score Identifies Cases with Poor Outcome in Patients with Early Chronic Phase Chronic Myeloid Leukemia, Though Not Predictive for Optimal Response to Imatinib 152
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 152
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 152
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 152
Sesquiterpene α-bisabolol, which binds to Bid in lipid rafts, induces apoptosis in BCR/ABL+ cell lines through membrane depolarization. 151
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 150
High incidence of autoimmune complications in 82 patients with non-MALT marginal zone lymphomas. 148
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 146
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 145
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association 144
Hyperchidam Verona897 Regimen Is Effective in Treatment of Advanced Peripheral T Cell Lymphoma (PTCL): The GITIL Experience in 33 Cases 143
Combination of EUTOS score and 3-months BCR-ABL transcript level identifies a distinct subgroup of ECP-CML patients with high risk of non optimal response and imatinib discontinuation. 143
Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases 142
BCR-ABL mutations in chronic myeloid leukemia (CML) patients (pts) with failure and warning to first- and second-lline tyrosine kinase inhibitor (TKI) therapy: what is the advantage of Next-Generation Sequencing (NGS) over conventional sequencing? 141
Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia 141
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 139
PBX/E2A transcript positive B-lymphoblastic leukemia (B-ALL) presenting with bilateral renal and myocardial involvement: a case report. 137
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 137
Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study. 135
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 134
High levels of tumor load reduction after intensive chemotherapy favorably affect the prognosis of BCR/ABL+ ALL adult patients receiving Imatinib Mesylate alone as a post-consolidation treatment according to the Italian GIMEMA LAL 0201/A protocol 132
Totale 18.166
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.508
article - articoli 67.042
book - libri 0
conference - conferenze 30.996
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 470
Totale 197.016
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202194 0 0 0 0 0 0 0 0 0 0 0 94
2021/20221.381 106 374 36 141 109 56 24 73 72 40 78 272
2022/20232.692 190 264 263 470 208 704 33 152 297 24 46 41
2023/20241.596 73 128 90 158 175 197 63 109 27 86 379 111
2024/20254.293 188 241 214 703 183 141 210 238 629 318 425 803
2025/202613.066 881 747 903 2.060 3.080 800 1.182 748 1.053 845 300 467
Totale 28.265